

CHIMERIX INC

Reported by

A.M. PAPPAS LIFE SCIENCE VENTURES III, L.P.

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 04/16/13 for the Period Ending 04/16/13

Address	2505 MERIDIAN PARKWAY, SUITE 340 DURHAM, NC 27713
Telephone	919.806.1074
CIK	0001117480
Symbol	CMRX
SIC Code	2834 - Pharmaceutical Preparations
Industry	Conglomerates
Sector	Conglomerates
Fiscal Year	12/31

FORM 4

[X] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL
 OMB Number: 3235-0287
 Estimated average burden hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *			2. Issuer Name and Ticker or Trading Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)	
A.M. Pappas Life Science Ventures IV LP			CHIMERIX INC [CMRX]		<input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input type="checkbox"/> Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) Stockholder	
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)			
			4/16/2013			
(Street)			4. If Amendment, Date Original Filed (MM/DD/YYYY)		6. Individual or Joint/Group Filing (Check Applicable Line)	
RESEARCH TRIANGLE PARK,, NC 27709					<input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person	
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	4/16/2013		C		892591	A	(1)	1047535 (3)	I	See Footnote (2)

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)	Date Exercisable	Expiration Date				
Series F Preferred Stock	(1)	4/16/2012		C		3168706	(1)	(1)	Common Stock	892591	\$0.00	0	I	See Footnote (2)

Explanation of Responses:

- (1) Upon the closing of the Issuer's initial public offering, every 3.55 shares of Series F Preferred Stock automatically converted into 1 share of Common Stock for no additional consideration and had no expiration date.
- (2) See attached Exhibit 99.1.
- (3) Includes 154,944 shares issued as payment of accrued dividends on the Series F Preferred Stock.

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
A.M. Pappas Life Science Ventures IV LP P.O. BOX 110287 RESEARCH TRIANGLE PARK,, NC 27709 PV IV CEO Fund, L.P.				Stockholder

P.O. BOX 110287 RESEARCH TRIANGLE PARK,, NC 277709				Stockholder
A.M. Pappas Life Science Ventures III, L.P. P.O. BOX 110287 RESEARCH TRIANGLE PARK,, NC 277709				Stockholder
PV III CEO Fund, L.P. P.O. BOX 110287 RESEARCH TRIANGLE PARK,, NC 277709				Stockholder

Signatures

: See Signatures Included in Exhibit 99.2

4/16/2013

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(2) The shares of Common Stock issuable upon conversion of the Preferred Stock are held as follows: 657,437 shares of common stock held by A.M. Pappas Life Science Ventures IV, L.P., 31,291 shares of common stock held by PV IV CEO Fund, L.P., 191,931 shares of common stock held by A.M. Pappas Life Science Ventures III, L.P. and 11,932 shares of common stock held by PV III CEO Fund, L.P. AMP&A Management IV, LLC is the general partner of each of A. M. Pappas Life Science Ventures IV, L.P. and PV IV CEO Fund, L.P. (collectively, the IV Funds), and AMP&A Management III, LLC is the general partner of each of A. M. Pappas Life Science Ventures III, L.P. and PV III CEO Fund, L.P. (collectively with the IV Funds, the Funds), and each of AMP&A Management IV, LLC and AMP&A Management III, LLC has a management agreement with A. M. Pappas & Associates, LLC whereby A. M. Pappas & Associates, LLC provides management services for the Funds. As a result, A. M. Pappas & Associates, LLC's investment committee exercises sole dispositive and voting power over the securities owned by the Funds. By virtue of these relationships, AMP&A Management IV, LLC, AMP&A Management III, LLC and A. M. Pappas & Associates, LLC may be deemed to beneficially own the securities owned directly by the Funds. Each of the foregoing entities disclaims beneficial ownership of such securities except to the extent of each of its pecuniary interest therein.

Signature of Reporting Persons:

This statement on Form 4 is filed by A.M. Pappas Life Science Ventures IV, L.P., PV IV CEO Fund, L.P., A.M. Pappas Life Science Ventures III, L.P. and PV III CEO Fund, L.P. The principal business address of each of the reporting persons is c/o A.M. Pappas & Associates, LLC, P.O. Box 110287, Research Triangle Park, NC 27709. The reporting entities disclaim beneficial ownership of the securities listed herein except to the extent of their pecuniary interest therein.

A.M. Pappas Life Science Ventures IV, L.P.

By: AMP&A Management IV, LLC

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

PV IV CEO Fund, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

A.M. Pappas Life Science Ventures III, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC

PV III CEO Fund, L.P.

By: /s/ Ford S. Worthy
Name: Ford S. Worthy
Title: Partner & CFO, A.M. Pappas &
Associates, LLC
